Clinical Scorecard: Creation and assessment of a predictive nomogram for osteoporosis risk in individuals with psoriasis
At a Glance
Category
Detail
Condition
Osteoporosis in psoriasis patients
Key Mechanisms
Chronic inflammation affecting bone remodeling and increased fracture risk due to glucocorticoid exposure.
Target Population
Patients with psoriasis, particularly those with psoriatic arthritis and other risk factors.
Care Setting
Dermatology and osteoporosis risk assessment.
Key Highlights
Developed a nomogram to predict osteoporosis risk in psoriasis patients.
Identified six independent risk factors for osteoporosis.
Nomogram demonstrated good discrimination with AUC of 0.824 in training and 0.771 in validation sets.
Osteoporosis prevalence in the study cohort was 11.7%.
Clinical utility confirmed through decision curve analysis.
Guideline-Based Recommendations
Diagnosis
Use dual-energy X-ray absorptiometry (DXA) for osteoporosis diagnosis with T-score ≤−2.5.
Management
Consider the nomogram for early identification of high-risk patients for DXA screening.
Monitoring & Follow-up
Regularly assess osteoporosis risk factors in psoriasis patients.
Risks
Increased risk of osteoporosis associated with advanced age, disease duration, psoriatic arthritis, vitamin D deficiency, systemic corticosteroid use, and male sex.
Patient & Prescribing Data
639 psoriasis patients included in the study.
Vitamin D levels and glucocorticoid exposure are critical factors in assessing osteoporosis risk.
Clinical Best Practices
Integrate osteoporosis risk assessment into routine care for psoriasis patients.
Utilize the nomogram to guide clinical decision-making for fracture prevention.
Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.
